A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 4, 2001, Pages 525-537

  Talley, N J ^a   Van Zanten, S V ^b   Saez, L R ^c   Dukes, G ^d   Perschy, T ^d   Heath, M ^d   Kleoudis, C ^d   Mangel, A W ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PAIN; PLACEBOS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 0035074588     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00941.x     Document Type: Article

References (40)

1. Functional gastroduodenal disorders
2. AGA technical review: Evaluation of dyspepsia
3. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact
4. Dyspepsia and dyspepsia subgroups: A population-based study
5. A national survey of practice patterns of gastroenterologists with comparison to the past two decades
6. Economic costs of functional dyspepsia
7. Identification of subgroups of functional gastrointestinal disorders
8. Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts
9. Gastric emptying rate of solids in patients with nonulcer dyspepsia
10. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up
11. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia
12. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity
13. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia
14. Abnormal visceral perception in patients with functional dyspepsia: Use of cerebral potentials evoked by electrical stimulation of the oesophagus
15. Role of visceral afferent mechanisms in functional bowel disorders
16. Roles played by 5-hydroxytryptamine in the physiology of the bowel
17. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension
18. 3-receptor antagonist, in patients with irritable bowel syndrome
19. 3 antagonism (ondansetron)
20. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist
21. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: A randomised placebo controlled study
22. Functional dyspepsia. A classification with guidelines for diagnosis and management
23. Functional bowel disorders and functional abdominal pain
24. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome
25. Statistical aspects of the analysis of data from retrospective studies of diseases
26. Review article: Gender-related differences in functional gastrointestinal disorders
27. Management of uninvestigated and functional dyspepsia: A Working Party report for the World Congresses of Gastroenterology 1998
28. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized placebo-controlled trials (the Bond and Opera studies)
29. Gastrointestinal sensory function in functional dyspepsia
30. Effects of tropisetron, a 5-HT3 receptor antagonist, on proximal gastric motor and sensory function in nonulcer dyspepsia
31. Alosetron does not affect the visceral perception of gastric distension in healthy subjects
32. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia?
33. Controlled treatment trials in the irritable bowel syndrome; A critique
34. Design of treatment trials for functional gastrointestinal disorders
35. Lack of association between gastric emptying of solids and symptoms in nonulcer dyspepsia
36. Alosetron, a 5-HT-3 receptor antagonist, delays colonic transit in patients with IBS and healthy volunteers
37. 3 antagonist, alosetron, in patients with carcinoid diarrhoea
38. Helicobacter pylori therapy is not effective for treatment of nonulcer dyspepsia: Meta-analysis of randomized controlled trials